IP10 levels linked to HBsAg decline during TDF treatment
Published on August 4, 2015 at 5:15 PM · No Comments
By Shreeya Nanda, Senior medwireNews Reporter
Baseline serum interferon-inducible protein 10 (IP10) levels predict hepatitis B surface antigen (HBsAg) reduction in patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B virus (HBV) infection treated with tenofovir disoproxil fumarate (TDF), findings indicate.
These results suggest that “IP10 levels can have clinical implications in the management of [chronic HBV] and may lead to novel immunomodulatory approaches”, says the team led by George Papatheodoridis (Athens University Medical School, Greece).
Among the 160 chronic HBV patients who started TDF therapy between 2008 and 2012, HBsAg levels reduced by a median of 0.08, 0.11, 0.24, 0.33 and 0.38 log10 IU/mL at 6, 12, 24, 36 and 48 months, respectively, relative to baseline. There were no significant changes between the 78 patients who had and the 82 patients who had not previously received nucleos(t)ide analogue (NA) treatment.
At the final assessment, 25% and 12% of all study participants attained a minimum 0.5 log10 IU/mL and 1.0 log10 IU/mL reduction in HBsAg levels, respectively.
And the cumulative rates of at least a 0.5 log10 IU/mL decline in HBsAg levels at 12, 24, 36 and 48 months were 8%, 16%, 24% and 41%, respectively. The corresponding rates for a minimum 1.0 log10 IU/mL decline in HBsAg levels were 4%, 10%, 12% and 15%.
In univariate analysis, both baseline HBsAg and IP10 levels were significantly associated with HBsAg reduction of at least 0.5 log10 IU/mL (p=0.004 and p=0.002, respectively), but in multivariate analysis, the association remained significant only for serum IP10 levels (p≤0.001).
Using a previously reported IP10 cutoff of 350 pg/dL, Papatheodoridis et al found that patients with baseline IP10 levels above compared with below the cutoff achieved HBsAg reduction of at least 0.5 log10 IU/mL significantly earlier (p<0.001).
“As HBV can limit the induction of antiviral defence mechanisms in the liver and higher serum IP10 levels probably reflecting an activated immune system are associated with favourable responses in [chronic HBV] patients, induction of IP-10 could represent a potential novel immunomodulatory approach in the treatment of [chronic HBV], as it has been recently tried in other diseases”, the researchers write in the Journal of Viral Hepatitis.
They add: “Additional evaluation of the usefulness of serum IP10 levels in [chronic HBV] patients who achieve HBsAg loss under long-term NA therapy will be of great interest.”
其中160慢性乙肝患者谁开始2008年和2012年间TDF治疗，HBsAg水平分别降低了0.08，0.11，0.24，0.33和0.38中位日志10 IU / mL的6，12，24，36和48个月，相对基线。有78例谁和谁没有以前收到的核苷（酸）类似物IDE（NA）治疗的82例患者之间没有显著的变化。
在最后的评估，25％和所有研究参与者的12％达到最低0.5日志10 IU / mL和1.0日志10 IU / mL的减少HBsAg水平，分别为。
和至少0.5日志10 IU /毫升下降HBsAg水平在12，24，36和48个月的累积率分别为8％，16％，24％和41％，分别为。最少1.0日志10 IU /毫升下降HBsAg水平相应率分别为4％，10％，12％和15％。
在单因素分析，基线HBsAg和IP10水平显著与乙肝表面抗原至少减少0.5日志10 IU / mL的相关（P = 0.004和p = 0.002，分别），但在多变量分析，该协会只针对血清IP10水平仍然显著（P≤0.001）。
使用先前报道的350微克/ dL的IP10截止，Papatheodoridis等人发现患者基线IP10水平高于与截止低于相比达到至少0.5日志10 IU /毫升的HBsAg还原显著较早（P <0.001）。